Trial · NCT00303719

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

NCT00303719, Phase 2, Terminated, Masonic Cancer Center, University of Minnesota; results first posted 2020-05-12

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy. Trials, record NCT00303719. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00303719

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
NCT number: NCT00303719
Status: Terminated
Phases: Phase 2
Enrollment: 342 participants, actual
Lead sponsor: Masonic Cancer Center, University of Minnesota
Conditions: Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: anti-thymocyte globulin, cyclophosphamide, cyclosporine, fludarabine, mycophenolate mofetil, stem cell transplantation, total body irradiation, filgrastim
First posted: 2006-03-17
Last updated: 2020-05-12
Results first posted: 2020-05-12

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Neutrophil and Donor Cell Engraftment	Day 42 and Day 100	Successful sustained engraftment is defined as primary neutrophil engraftment by day 42 and e90% donor cells at day 100, with or without DLI. Engraftment based on absolute neutrophil count of donor origin \> 0.5 x 10e9 /L for 3 days by day 42
Secondary	Serious Adverse Events	Day 100	Safety by development of severe adverse events within 100 days of transplant
Secondary	Transplant Related Mortality	Day 100	\> 30% transplant related mortality at 100 days (non-relapse).
Secondary	Overall Survival	1 year
Secondary	Acute Graft-Versus-Host Disease	Day 100	Grade III-IV graft versus host disease

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Neutrophil and Donor Cell Engraftment	Day 42 and Day 100	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Serious Adverse Events	Day 100	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Transplant Related Mortality	Day 100	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Overall Survival	1 year	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Acute Graft-Versus-Host Disease	Day 100	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group10

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Neutrophil and Donor Cell Engraftment	High Risk Patients	12	Participants
Neutrophil and Donor Cell Engraftment	Standard Risk Patients	289	Participants
Serious Adverse Events	High Risk Patients	0	Participants
Serious Adverse Events	Standard Risk Patients	47	Participants
Transplant Related Mortality	High Risk Patients	2	Participants
Transplant Related Mortality	Standard Risk Patients	40	Participants
Overall Survival	High Risk Patients	8	Participants
Overall Survival	Standard Risk Patients	181	Participants
Acute Graft-Versus-Host Disease	High Risk Patients	2	Participants
Acute Graft-Versus-Host Disease	Standard Risk Patients	79	Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	High Risk Patients	13
Overall Study	STARTED	Standard Risk Patients	329
Overall Study	COMPLETED	High Risk Patients	13
Overall Study	COMPLETED	Standard Risk Patients	292
Overall Study	NOT COMPLETED	High Risk Patients	0
Overall Study	NOT COMPLETED	Standard Risk Patients	37

Source ClinicalTrials.gov

Adverse events50

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Acute respiratory distress syndrome (ARDS)	Respiratory, thoracic and mediastinal disorders	High Risk Patients	0	13	0
other	Acute respiratory distress syndrome (ARDS)	Respiratory, thoracic and mediastinal disorders	Standard Risk Patients	17	292	18
other	Bacterial infection	Infections and infestations	High Risk Patients	5	13	15
other	Bacterial infection	Infections and infestations	Standard Risk Patients	128	292	334
other	Bleeding	Gastrointestinal disorders	High Risk Patients	2	13	4
other	Bleeding	Gastrointestinal disorders	Standard Risk Patients	45	292	56
other	Cystitis	Renal and urinary disorders	High Risk Patients	1	13	1
other	Cystitis	Renal and urinary disorders	Standard Risk Patients	15	292	18
other	Hemodialysis	Renal and urinary disorders	High Risk Patients	2	13	2
other	Hemodialysis	Renal and urinary disorders	Standard Risk Patients	18	292	21

1 to 10 of 50Source ClinicalTrials.gov

See all 50 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	High Risk Patients	6	13
Total, all-cause mortality	Standard Risk Patients	124	292
Total, other adverse events	High Risk Patients	12	13
Total, other adverse events	Standard Risk Patients	272	292
Total, serious adverse events	High Risk Patients	1	13
Total, serious adverse events	Standard Risk Patients	53	292

Source ClinicalTrials.gov

Papers5

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
19179301	DERIVED	PubMed
21403127	DERIVED	PubMed
22408257	BACKGROUND	PubMed
22430088	DERIVED	PubMed
30077015	BACKGROUND	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons7

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
High Risk Patients vs Standard Risk Patients: Acute Graft-Versus-Host Disease	Trial comparisons
High Risk Patients vs Standard Risk Patients: Serious Adverse Events	Trial comparisons
High Risk Patients vs Standard Risk Patients: Overall Survival	Trial comparisons
High Risk Patients vs Standard Risk Patients: Transplant Related Mortality	Trial comparisons
High Risk Patients vs Standard Risk Patients: deaths from any cause	Trial comparisons
High Risk Patients vs Standard Risk Patients: Neutrophil and Donor Cell Engraftment	Trial comparisons
High Risk Patients vs Standard Risk Patients: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00303719

GET https://conductscience.org/api/trials/v1/NCT00303719/events?page=2

API reference For AI assistants